<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2410-1893-2022-9-4-11</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-838</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клинические наблюдения</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical Case Reports</subject></subj-group></article-categories><title-group><article-title>Случай повторного применения необратимой электропорации при местнораспространенном раке поджелудочной железы</article-title><trans-title-group xml:lang="en"><trans-title>Repeated irreversible electroporation in a locally advanced pancreatic cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5348-5011</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Поляков</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Polyakov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Поляков Александр Николаевич – кандидат медицинских наук, старший научный сотрудник онкологического отделения хирургических методов лечения № 7 (опухолей гепатопанкреатобилиарной зоны)</p><p>115478, г. Москва, Каширское шоссе, д. 24</p><p>SPIN: 9924-0256,</p><p>AuthorID: 764535,</p><p>Scopus Author ID: 57190413973</p></bio><bio xml:lang="en"><p>Alexandr N. Polyakov – Cand. Sci. (Med.), senior researcher of the oncology department of surgical treatment methods No. 7 (tumors of the hepatopancreatobiliary zone)</p><p>24 Kashirskoye sh., Moscow 115478</p><p>SPIN: 9924-0256,</p><p>AuthorID: 764535.</p><p>Scopus Author ID: 57190413973</p></bio><email xlink:type="simple">dr.alexp@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7375-3378</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подлужный</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Podluzhnyi</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Подлужный Данила Викторович – кандидат медицинских наук, заведующий онкологическим отделением хирургических методов лечения № 7 (опухолей гепатопанкреатобилиарной зоны)</p><p>Москва</p><p>SPIN: 3537-3436,</p><p>AuthorID: 583879,</p><p>Scopus Author ID: 6506558213</p></bio><bio xml:lang="en"><p>Danila V. Podluzhnyi – Cand. Sci. (Med.), head of the oncology department of surgical treatment methods No. 7 (tumors of the hepatopancreatobiliary zone)</p><p>Moscow</p><p>SPIN: 3537-3436,</p><p>AuthorID: 583879,</p><p>Scopus Author ID: 6506558213</p></bio><email xlink:type="simple">danil-p@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0504-585X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кудашкин</surname><given-names>Н. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kudashkin</surname><given-names>N. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кудашкин Николай Евгеньевич – кандидат медицинских наук, старший научный сотрудник онкологического отделения хирургических методов лечения № 7, (опухолей гепатопанкреатобилиарной зоны)</p><p>Москва</p><p>SPIN: 3574-8344,</p><p>AuthorID: 865983,</p><p>ResearcherID: R-8764-2019,</p><p>Scopus Author ID: 54885375500</p></bio><bio xml:lang="en"><p>Nikolay E. Kudashkin – Cand. Sci. (Med.), the senior researcher of the oncology department of surgical treatment methods No. 7 (tumors of the hepatopancreatobiliary zone)</p><p>Moscow</p><p>SPIN: 3574- 8344,</p><p>AuthorID: 865983,</p><p>ResearcherID: R-8764-2019,</p><p>Scopus Author ID: 54885375500</p></bio><email xlink:type="simple">dr.kudashkin@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2624-9341</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Базин</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Bazin</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Базин Игорь Сергеевич – ведущий научный сотрудник отделения лекарственных методов лечения (химиотерапевтическое) № 2</p><p>Москва</p><p>SPIN: 2186-5878,</p><p>AuthorID: 266861,</p><p>ResearchID: J-6618-2017,</p><p>Scopus Author ID: 000326249341</p></bio><bio xml:lang="en"><p>Igor S. Bazin – leading researcher of the second chemotherapeutic department</p><p>Moscow</p><p>SPIN: 2186-5878,</p><p>AuthorID: 266861,</p><p>ResearchID: J-6618-2017,</p><p>Scopus Author ID: 000326249341</p></bio><email xlink:type="simple">bazin_onk@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1779-003X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Медведева</surname><given-names>Б. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Medvedeva</surname><given-names>B. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Медведева Бэла Михайловна – доктор медицинских наук, заведующая рентгенодиагностическим отделением</p><p>Москва</p><p>SPIN: 1160-2169,</p><p>AuthorID: 583878,</p><p>Scopus Author ID: 56563956800</p></bio><bio xml:lang="en"><p>Bela M. Medvedeva – Dr. Sci. (Med.), head of radiology department, scientific research institute of clinical and experimental radiology</p><p>Moscow</p><p>SPIN: 1160-2169,</p><p>AuthorID: 583878,</p><p>Scopus Author ID: 56563956800</p></bio><email xlink:type="simple">m-diagnostica@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7163-2089</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сыскова</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Syskova</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сыскова Анна Юрьевна – врач-онколог отделения химиотерапии № 2</p><p>Москва</p><p>SPIN: 1676-6072,</p><p>AuthorID: 1118447</p></bio><bio xml:lang="en"><p>Anna Yu. Syskova – medical oncologist, department of chemotherapy No. 2</p><p>Moscow</p><p>SPIN: 1676-6072,</p><p>AuthorID: 1118447</p></bio><email xlink:type="simple">kasterpriz@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3953-0036</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кантиева</surname><given-names>Д. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kantieva</surname><given-names>D. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кантиева Даяна Магомедовна – врач онколог, отделение лекарственных методов лечения (химиотерапевтическое) № 2</p><p>Москва</p><p>ResearchID: GLV-5759-2022</p></bio><bio xml:lang="en"><p>Dayana M. Kantieva – oncologist of the second chemotherapeutic department</p><p>Moscow</p><p>ResearchID: GLV-5759-2022</p></bio><email xlink:type="simple">kantieva96@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9254-1346</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Патютко</surname><given-names>Ю. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Patyutko</surname><given-names>Yu. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Патютко Юрий Иванович – доктор медицинских наук, профессор, главный научный консультант онкологического отделения хирургических методов лечения № 7, (опухолей гепатопанкреатобилиарной зоны)</p><p>Москва</p><p>AuthorID: 137980</p></bio><bio xml:lang="en"><p>Yuriy I. Patyutko – Dr. Sci. (Med.), chief adviser of the oncology department of surgical treatment methods No. 7 (tumors of the hepatopancreatobiliary zone)</p><p>Moscow</p><p>AuthorID: 137980</p></bio><email xlink:type="simple">mikpat@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НМИЦ онкологии им. Н. Н. Блохина</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N. N. Blokhin National Medical Research Center of Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Городская клиническая онкологическая больница № 1</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Clinical Oncological Hospital No. 1</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>01</day><month>12</month><year>2022</year></pub-date><volume>9</volume><issue>4</issue><fpage>114</fpage><lpage>122</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Поляков А.Н., Подлужный Д.В., Кудашкин Н.Е., Базин И.С., Медведева Б.М., Сыскова А.Ю., Кантиева Д.М., Патютко Ю.И., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Поляков А.Н., Подлужный Д.В., Кудашкин Н.Е., Базин И.С., Медведева Б.М., Сыскова А.Ю., Кантиева Д.М., Патютко Ю.И.</copyright-holder><copyright-holder xml:lang="en">Polyakov A.N., Podluzhnyi D.V., Kudashkin N.E., Bazin I.S., Medvedeva B.M., Syskova A.Y., Kantieva D.M., Patyutko Y.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/838">https://www.rpmj.ru/rpmj/article/view/838</self-uri><abstract><p>При местнораспространенном нерезектабельном раке поджелудочной железы (РПЖ) целесообразно рассмотреть техническую возможность и онкологическую обоснованность локальной деструкции опухоли. Необратимая электропорация (НЭП) – нетермический метод локальной абляции опухоли, зону воздействия которого можно контролировать расположением электродов. Под воздействием нетепловой энергии высоковольтных ультракоротких электрических полей, локализованных между электродами, в клеточной оболочке образуются постоянные нанопоры, что приводит к нарушению клеточного гомеостаза и гибели клетки. Достаточно четкая и контролируемая граница абляции без клинически значимой зоны перифокального повреждения тканей снижает риск случайного воздействия на окружающие органы и структуры, в первую очередь – стенку полого органа. Метод основан на изменении проницаемости клеточной мембраны и развитии апоптоза, что позволяет воздействовать непосредственно на инфильтрированные опухолью протоки и магистральные сосуды без высокого риска их повреждения. Представленный случай показывает, что НЭП целесообразно использовать в плане комбинированного лечения больных местнораспространенном РПЖ. Не отмечено осложнений ни после первого, ни после второго сеансов НЭП. Методы лучевой диагностики, а также морфологические исследования показали возможность адекватного локального контроля. Также получены неплохие результаты в общей продолжительности жизни, учитывая, что речь идет о нерезектабельной протоковой аденокарциноме поджелудочной железы. Больная прожила 39 месяцев от начала лечения и 26 месяцев от первого сеанса НЭП. В случае местного рецидива также возможна повторная электропорация с хорошим отдаленным результатом. Время до прогрессирования превысило одиннадцать месяцев после электропорации, выполненной по поводу локального рецидива. По данным магнитно-резонансной томографии выявлен как локорегионарный рецидив, так и отдаленные метастазы в печени. Пациентка прожила 16 месяцев после повторного сеанса НЭП и умерла от тромбоэмболии легочной артерии на фоне начатой химиотерапии. Благоприятными прогностическими факторами являются наличие объективного ответа на предшествующее консервативное лечение, соблюдение параметров электропорации, полное включение опухолевой инфильтрации в зону воздействия.</p></abstract><trans-abstract xml:lang="en"><p>It is reasonable to consider the technical possibility and oncological feasibility of the local tumor destruction in patients with locally advanced pancreatic cancer (PCa). Irreversible electroporation (IRE) is a non-thermal method of local tumor ablation, which uses non-thermal energy of high-voltage ultrashort electric fields localized between electrodes to create nanopores in the cellular wall with the following cellular death. The zone of impact can be accurately predicted using the location of the electrodes. A fairly clear and controlled ablation boundary without a clinically significant zone of perifocal tissue damage reduces the risk of accidental injury to the wall of a hollow organ. The method is based on a change in the permeability of the cell membrane and the development of apoptosis, which allows to act directly on the ducts and the great vessels infiltrated by the tumor without a high risk of damage. The presented case shows that IRE is advisable to use as a part of the combined treatment of patients with locally advanced PCa. There were no complications observed after the IRE. Radiological evaluations and pathologic reports showed an adequate long-term local control. Also, good results were obtained in the overall life expectancy, given that we are talking about unresectable ductal adenocarcinoma of the pancreas. The patient passed away in 39 months from the beginning of the treatment and in 26 months from the initial IRE. In case of local relapse, repeated electroporation with a good long-term result is also possible. The time to progression exceeded eleven months after electroporation performed for a local relapse. According to magnetic resonance imaging, both locoregional relapse and distant liver metastases were detected. The patient lived 16 months after a repeated IRE session and died of pulmonary embolism on the background of chemotherapy. Favorable prognostic factors are the presence of an objective response to previous conservative treatment, compliance with the parameters of electroporation, complete inclusion of tumor infiltration in the affected area.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нерезектабельный неметастатический рак поджелудочной железы</kwd><kwd>протоковая аденокарцинома</kwd><kwd>локальный рецидив рака поджелудочной железы</kwd><kwd>необратимая электропорация</kwd><kwd>комбинированное лечение рака поджелудочной железы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>unreseсtable non-metastatic pancreatic cancer</kwd><kwd>ductal adenocarcinoma</kwd><kwd>local relapse of pancreatic cancer</kwd><kwd>irreversible electroporation</kwd><kwd>combined treatment for pancreatic cancer</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492</mixed-citation><mixed-citation xml:lang="en">Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB 3rd, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Aug 1;34(22):2654–2668. https://doi.org/10.1200/JCO.2016.67.5561</mixed-citation><mixed-citation xml:lang="en">Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB 3rd, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Aug 1;34(22):2654–2668. https://doi.org/10.1200/JCO.2016.67.5561</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol. Clin. Oncol. 2016;4:315– 325. https://doi.org/10.3892/mco.2015.716</mixed-citation><mixed-citation xml:lang="en">Gong J, Tuli R, Shinde A, Hendifar AE. Meta-analyses of treatment standards for pancreatic cancer. Mol. Clin. Oncol. 2016;4:315– 325. https://doi.org/10.3892/mco.2015.716</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vogel JA, van Veldhuisen E, Agnass P, Crezee J, Dijk F, Verheij J, et al. Time-dependent impact of irreversible electroporation on pancreas, liver, blood vessels and nerves: a systematic review of experimental studies. PLoS ONE. 2016;11(11):e0166987. https://doi.org/10.1371/journal.pone.0166987</mixed-citation><mixed-citation xml:lang="en">Vogel JA, van Veldhuisen E, Agnass P, Crezee J, Dijk F, Verheij J, et al. Time-dependent impact of irreversible electroporation on pancreas, liver, blood vessels and nerves: a systematic review of experimental studies. PLoS ONE. 2016;11(11):e0166987. https://doi.org/10.1371/journal.pone.0166987</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Martin RC 2nd, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, et al. Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation Safety and Efficacy. Ann Surg 2015;262:486–494. https://doi.org/10.1097/SLA.0000000000001441</mixed-citation><mixed-citation xml:lang="en">Martin RC 2nd, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, et al. Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation Safety and Efficacy. Ann Surg 2015;262:486–494. https://doi.org/10.1097/SLA.0000000000001441</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Астахов Д. А., Панченков Д. Н., Иванов Ю. В., Шабловский О. Р., Кедрова А. Г., Соловьев Н. А. и др. Необратимая электропорация при местнораспространенном раке поджелудочной железы. Анналы хирургической гепатологии. 2018;23(2):59–68. https://doi.org/10.16931/1995-5464.2018259-68</mixed-citation><mixed-citation xml:lang="en">Astakhov DA, Panchenkov DN, Ivanov YuV, Shablovsky OR, Kedrova AG, Soloviev NA, et al. Irreversible electroporation for locally advanced pancreatic cancer. Annaly khirurgicheskoy gepatologii = Annals of HPB surgery. 2018;23(2):59–68. (In Russ.). https://doi.org/10.16931/1995-5464.2018259-68</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med 2013;369:1691–1703. https://doi.org/10.1056/NEJMoa1304369</mixed-citation><mixed-citation xml:lang="en">Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med 2013;369:1691–1703. https://doi.org/10.1056/NEJMoa1304369</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer N Engl J Med 2011;364:1817–1825. https://doi.org/10.1056/NEJMoa1011923</mixed-citation><mixed-citation xml:lang="en">Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer N Engl J Med 2011;364:1817–1825. https://doi.org/10.1056/NEJMoa1011923</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019 May 19;11:1758835919850367. https://doi.org/10.1177/1758835919850367</mixed-citation><mixed-citation xml:lang="en">Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Ther Adv Med Oncol. 2019 May 19;11:1758835919850367. https://doi.org/10.1177/1758835919850367</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324</mixed-citation><mixed-citation xml:lang="en">Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315(17):1844–1853. https://doi.org/10.1001/jama.2016.4324</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ионкин Д. А., Карельская Н. А., Степанова Ю. А., Земсков В. М., Козлова М. Н., Жаворонкова О. А. и др. Криодеструкция при местнораспространенном раке поджелудочной железы. Анналы хирургической гепатологии. 2018;23(2):37–49. https://doi.org/10.16931/1995-5464.2018237-49</mixed-citation><mixed-citation xml:lang="en">Ionkin DA, Karelskaya NA, Stepanova YuA, Zemskov VМ, Kozlova MN, Zhavoronkova OA, et al. Cryoablation for locally аdvanced pancreatic cancer. Annals of HPB surgery. 2018;23(2):37–49. (In Russ.). https://doi.org/10.16931/1995-5464.2018237-49</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Transactions on Bio-medical Engineering 2006;53:1409–1415. https://doi.org/10.1109/TBME.2006.873745</mixed-citation><mixed-citation xml:lang="en">Edd JF, Horowitz L, Davalos RV, Mir LM, Rubinsky B. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Transactions on Bio-medical Engineering 2006;53:1409–1415. https://doi.org/10.1109/TBME.2006.873745</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingstone AS, et al. Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma. J Vasc Interv Radiol 2012;23:1613–1621. https://doi.org/10.1016/j.jvir.2012.09.012</mixed-citation><mixed-citation xml:lang="en">Narayanan G, Hosein PJ, Arora G, Barbery KJ, Froud T, Livingstone AS, et al. Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma. J Vasc Interv Radiol 2012;23:1613–1621. https://doi.org/10.1016/j.jvir.2012.09.012</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
